



Klaria signs exclusive development, license and supply agreements with Purdue Pharma (Canada) for the emergency treatment of anaphylactic reactions

Klaria has signed exclusive agreements with Purdue Pharma (Canada) for the development, licensing and manufacture of an emergency treatment for severe allergic reactions.

Uppsala, Sweden and Pickering, Canada, 22 January, 2019 – Klaria AB (Klaria) (Parent Company, Klaria Pharma Holding AB, Stockholm OMX Nasdaq:KLAR) and Purdue Pharma (Canada) today announced they have entered into an exclusive development agreement for KL-01401 (Epinephrine Oromucosal Film). KL-01401 is a developmental stage formulation of epinephrine for emergency treatment of severe anaphylactic reactions in patients who are at increased risk for anaphylaxis. KL-01401 will be co-developed by Klaria and Purdue Pharma (Canada). The development agreement includes exclusive global license and supply options for the independently associated Purdue/Napp/Mundipharma network of companies upon achievement of defined milestones.

Under the terms of the agreement, the total value of all milestones achievable is 55.2 million US Dollars. In addition, Klaria will receive mid-to-upper single digit royalties on net sales. Further terms of the agreements give Klaria exclusive manufacturing rights to supply the global market with KL-01401.

In order to complete the agreement with Purdue, Klaria AB has also added epinephrine to its license agreement with Uppsalagruppen Medical AB. In the agreement between Klaria and Uppsalagruppen, Uppsalagruppen will receive a four percent royalty on Klaria's net income from sales of KL-01401.

KL-01401 is based on Klaria's novel patented drug delivery platform, which provides several benefits to patients who may require emergency treatment, for anaphylactic reactions. It is planned as an easy to use, non-injectable self-administered treatment that allows patients and their caregivers to discreetly carry a life-saving emergency treatment medication with them at all times.

Dr. Scott Boyer, CEO, Klaria commented: "We are extremely pleased and encouraged to enter into this agreement with Purdue – our second collaboration to date. This agreement combines the strengths of our patented drug delivery platform with a partner who is a leader in development and commercialization of innovative treatments. We are confident that the result of our partnership will meet an unmet medical need for patients relying on epinephrine in the event of a severe allergic reaction."

David Pidduck, President and CEO of Purdue Pharma (Canada) commented: "Today's agreement signals an exciting move for Purdue as we endeavour to shift the treatment paradigm for Canadians living with the threat of an anaphylactic reaction. Anaphylaxis is the most serious type of allergic reaction and current treatment options continue to face increasing challenges, including availability. The deepening of our partnership with Klaria by entering into a second development agreement with them is another example of our commitment to investing in new technologies and treatment options that will make a positive impact on the healthcare system and on patients' lives. This agreement is consistent with our overall strategy of expanding opportunities through business development."

About Klaria AB

Klaria develops innovative products with clear medical benefits for patients in need of rapid, reliable treatment. Klaria's products are based on a patented drug delivery film which is combined with clinically-tested and established active drugs substances. Klaria is listed on Nasdaq First North under the name KLAR. FNCA Sweden (info@fnca.se, +46(0) 8-528 00 399) is the Certified Advisor for Klaria Pharma Holding AB. The complete company description can be downloaded from www.klaria.com

About Purdue Pharma (Canada)

Purdue Pharma (Canada) is a research-based pharmaceutical and consumer healthcare company which has operated in Canada for more than 60 years. Its employees are committed to improving the health and quality of life of Canadians. The company has a broad portfolio of prescription and non-prescription medications including: prescription treatments for pain, ADHD, chemotherapy-induced nausea and vomiting (CINV), various ophthalmic conditions and OTC products. The company supports evidence-based education for the safe use of its products. Its headquarters, located in Pickering, ON, include integrated research & development, formulation and manufacturing operations. Privately held and founded by physicians, Purdue Pharma (Canada) is independently associated with the worldwide Purdue/Napp/Mundipharma network of companies. Learn more at www.purdue.ca

Media Inquiries:

Klaria AB

Scott Boyer, CEO, Klaria Pharma Holding AB (publ)

scott.boyer@klaria.com

Tel: +46 (0) 8-446 42 99 / +46 (0) 730-71 64 62

www.klaria.com

Purdue Pharma (Canada)

Lisa Joyce, Head of Communications

Purdue Pharma (Canada)

Pickering, ON, Kanada

media@purdue.ca

Klaria Pharma Holding AB is obliged to publish this information in accordance with the EU Market Abuse Regulations. The information was provided through the above contact person for publication on January 22, 2019 at 14:30 CET.

For more information, visit the Klaria Pharma Holding website klaria.com or contact:

Scott Boyer, CEO Klaria Pharma Holding AB (publ)

scott.boyer@klaria.com

Tel: +46 8-446 42 99 / +46 730-71 64 62

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, fast-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North under the short name KLAR. FNCA Sweden (info@fnca.se, +46(0) 8-528 00 399) is Certified Advisor for Klaria Pharma Holding AB. For more information, see www.klaria.com.